ARCH Venture Partners X, LLC

ARCH Venture Partners X bought 1,915,700 shares of NMRA at $2.61 for $5.0M, raising stake to 6,046,907 shares; stock down 81.7% from $13.64 high.

ARCH Venture Partners X, a 10% owner, purchased 1,915,700 shares (1.92M shares) at $2.61 on 2025-10-27 for $5.0M, increasing holdings by 46.4% to 6,046,907 shares (6.05M shares). The transaction occurred as NMRA trades at $2.50, down 81.7% from its 52-week high of $13.64, despite a recent +42.0% 30-day recovery. Prior trades by this investor at NMRA—two buys on 2023-09-19—both posted negative 90-day returns (-13.6%), indicating poor historical timing at this ticker. The company reported a net loss of $52,731,000 ($-52.7M) for its most recent full fiscal year, underlining ongoing cash burn. A cluster buy pattern is present, with 2 other insiders also acquiring shares within the past 14 days, which provides some incremental validation, though the persistence of fundamental unprofitability and the shareholder's own historical execution challenges at this ticker remain material considerations.

ARCH Venture Partners X bought 3,030,300 shares of PRME at $3.30 ($10.0M), boosting stake 94.7% to 6,230,300 shares

ARCH Venture Partners X, a 10% owner of Prime Medicine, purchased 3,030,300 shares at $3.30 on 2025-08-01 for $9,999,990.00, expanding its position from 3,200,000 to 6,230,300 shares. The company remains deeply unprofitable with a net loss of $-51,890,000.00 against minimal revenue of $1,454,000.00, though the stock has recovered +31.6% over 30 days and +140.5% over 90 days from a 52-week low. The prior ARCH purchase at this ticker on 2024-02-15 achieved positive returns at both the 30-day (+14.6%) and 90-day (+8.2%) intervals, establishing a successful historical precedent. A cluster of 3 other insiders also bought within the past 14 days, suggesting aligned investor interest despite the company's ongoing cash-burn profile.